OverviewSuggest Edit

G1 is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of cancer. The Company focuses on cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells, and represents a recently validated and promising class of targets for anti-cancer therapeutics.
TypePublic
Founded2008
HQDurham, US
Websiteg1therapeutics.com

Latest Updates

Employees (est.) (Feb 2019)44
Job Openings18
Revenue (FY, 2017)$0
Share Price (Mar 2019)$15.7 (-1%)

Key People/Management at G1 Therapeutics

Mark Velleca

Mark Velleca

CEO
Rajesh Malik

Rajesh Malik

Chief Medical Officer
Jay Strum

Jay Strum

Chief Scientific Officer
Greg Mossinghoff

Greg Mossinghoff

Chief Business Officer
Show more

G1 Therapeutics Office Locations

G1 Therapeutics has an office in Durham
Durham, US (HQ)
79 TW Alexander Dr
Show all (1)
Report incorrect company information

G1 Therapeutics Financials and Metrics

G1 Therapeutics Revenue

USD

Net income (FY, 2018)

(85.3m)

EBIT (FY, 2018)

(89.3m)

Market capitalization (15-Mar-2019)

587.3m

Closing stock price (15-Mar-2019)

15.7

Cash (31-Dec-2018)

369.3m
G1 Therapeutics's current market capitalization is $587.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

522.0k

Revenue growth, %

(100%)

General and administrative expense

3.2m5.2m7.1m18.6m

R&D expense

12.7m25.2m53.9m70.7m
Quarterly
USDQ3, 2017Q2, 2018

General and administrative expense

1.9m3.3m

R&D expense

14.1m18.4m

Operating expense total

15.9m21.7m

EBIT

(15.9m)(21.7m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

47.3m103.8m369.3m

Prepaid Expenses

596.0k849.0k

Current Assets

47.9m104.7m370.1m

PP&E

311.0k510.0k1.1m
Quarterly
USDQ3, 2017Q2, 2018

Cash

118.4m188.2m

Current Assets

119.0m189.9m

PP&E

516.0k711.0k

Total Assets

119.6m190.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(20.3m)(30.3m)(60.1m)(85.3m)

Depreciation and Amortization

42.0k67.0k89.0k175.0k

Accounts Payable

1.7m3.4m6.3m(1.0m)

Cash From Operating Activities

(13.8m)(25.1m)(50.5m)(74.3m)
Quarterly
USDQ3, 2017

Net Income

(43.1m)

Depreciation and Amortization

59.0k

Accounts Payable

5.0m

Cash From Operating Activities

(35.8m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information

G1 Therapeutics News and Updates

G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 27, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference. The…

G1 Therapeutics stock dives on cancer-related infection drug study results

G1 Therapeutics Inc. shares dropped in the extended session Wednesday after the biotech drug maker said one of its drugs met endpoints in a clinical study but had not done as well as other metrics versus a placebo treatment. G1 Therapeutics shares, which had been halted after hours, fell 24% after …

G1 Therapeutics Announces Positive Myelopreservation Data from Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Trilaciclib in Combination with Chemotherapy/Tecentriq® in First-Line Small Cell Lung Cancer

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2018 (GLOBE NEWSWIRE) --  G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with chemotherap…

G1 Therapeutics to Present Preliminary Data from Randomized Phase 2 Trial of Trilaciclib in Metastatic Triple-Negative Breast Cancer at 2018 San Antonio Breast Cancer Symposium (SABCS)

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that preliminary data from its randomized Phase 2 clinical trial of trilaciclib in combination with chemotherapy for the treatment of metastatic …

G1 Therapeutics Reports Third Quarter 2018 Financial Results and Corporate Update

Positive data from randomized Phase 2 trilaciclib/chemotherapy trial in first-line small cell lung cancer presented at ESMO 2018 highlight myelopreservation and immune system benefits of trilaciclib

G1 Therapeutics to Present at Investor Conferences in November 2018

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D., will provide a company overview at the following upcoming investor conferences in Novembe…
Show more
Report incorrect company information

G1 Therapeutics Blogs

G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. , March 04, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced Chief Executive Officer Mark Velleca , M.D., Ph.D., will present a company overview at the Cowen and Company 39 th Annual Healthcare Conference.

G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results

Reported positive findings in all four randomized Phase 2 clinical trials of trilaciclib in 2018 Clinical program updates to be provided at Investor Day 2019 on March 6 Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C. , Feb.

G1 Therapeutics to Host Investor Day 2019 on March 6, 2019

RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in New York City , beginning at 8:00 a.m.

G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019

RESEARCH TRIANGLE PARK, N.C. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to report financial results for the fourth quarter and full-year 2018 on Thursday, February 28,

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer

Achieved both primary endpoints: statistically significant reductions in the duration and occurrence of Grade 4 neutropenia Clinically meaningful reductions in rates of granulocyte-colony stimulating factor (G-CSF) usage and red blood cell ( RBC ) transfusions Safety profile consistent with

G1 Therapeutics Frequently Asked Questions

  • When was G1 Therapeutics founded?

    G1 Therapeutics was founded in 2008.

  • Who are G1 Therapeutics key executives?

    G1 Therapeutics's key executives are Mark Velleca, Rajesh Malik and Jay Strum.

  • How many employees does G1 Therapeutics have?

    G1 Therapeutics has 44 employees.

  • Who are G1 Therapeutics competitors?

    Competitors of G1 Therapeutics include Burzynski Research Institute, GTx and Rexahn Pharmaceuticals.

  • Where is G1 Therapeutics headquarters?

    G1 Therapeutics headquarters is located at 79 TW Alexander Dr, Durham.

  • Where are G1 Therapeutics offices?

    G1 Therapeutics has an office in Durham.

  • How many offices does G1 Therapeutics have?

    G1 Therapeutics has 1 office.